Ompekimig clinical trials
Also written PF-07264660.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses ompekimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PF-07264660
- 2
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ompekimig.
Studies
Open first, then newest update. How each study uses ompekimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisActive, not recruitingPhase 2PfizerNCT05995964Written as PF-07264660
- A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult ParticipantsCompletedPhase 1PfizerNCT06712082Written as PF-07264660
- A Preliminary Study to Evaluate PF-07264660 in Healthy ParticipantsCompletedPhase 1PfizerNCT05496738Written as PF-07264660 intravenous single ascending dose
Codes
What other systems call ompekimig · ClinicalTrials.gg INT015525
- UNII (FDA) 7S9F79AD9ZOMPEKIMIGOne source FDA
- NCI Thesaurus C211744OmpekimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7S9F79AD9Z | OMPEKIMIG | One source FDA |
| NCI Thesaurus | C211744 | Ompekimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.